• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Quick Take: Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma

byDonna LeetandAliya Ramjaun
June 28, 2019
in Gastroenterology, Oncology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Neoadjuvant chemotherapy plus surgery improves overall survival compared to surgery alone in locally advanced esophageal cancer

#VisualAbstract: Positron emission tomography effective at assessing early tumor response to induction chemotherapy in esophageal or esophagogastric junction cancers

#VisualAbstract: Dose-escalated concurrent chemoradiotherapy does not improve survival in locally advanced esophageal cancer

Current international guidelines recommend a combination of perioperative chemotherapy and surgery in the treatment of operable gastroesophageal cancer. However, given high mortality rates in patients treated with contemporary perioperative chemotherapy, more clinically efficacious and less toxic regimens are needed. One potential strategy involves combining anti-HER2 agents, such as lapatinib, with neoadjuvant chemotherapy. In this randomized controlled open-label trial, 46 patients with HER2-positive operable gastroesophageal adenocarcinoma were assigned to receive either standard epirubicin, cisplatin, and capecitabine (sECX) or modified ECX plus lapatinib (mECX+L) to determine the safety of adding lapatinib to ECX chemotherapy and to establish a recommended treatment dose for a phase 3 trial. The primary outcome was the proportion of patients experiencing grade 3 or 4 diarrhea with mECX+L. Researchers found that the primary outcome occurred in more patients in the mECX+L group than in the sECX group (21% vs. 0%, respectively). In addition, more patients in the mECX+L arm stopped preoperative treatment early compared to patients in the sECX arm (15% vs. 4%, respectively). The most common preoperative toxic effect in both groups was neutropenia, and toxic effects more common in the mECX+L group included grade 1 or 2 stomatitis and vomiting. Postoperative complication rates were similar in each group, and the rate of toxic effects in the postoperative setting was similar to that in the preoperative setting. This study was limited by its small sample size. Importantly, the FLOT (fluorouracil, oxaliplatin, leucovorin, and docetaxel) regimen was adopted as the new perioperative standard of care in place of ECX after recruitment for this study had been completed, limiting the external validity of the study. Overall, this study suggests lapatinib in addition to ECX may be feasible for the treatment of HER2-positive gastroesophageal adenocarcinoma, although better regimens with less toxic effects, such as FLOT, are being investigated in combination with non-cardiotoxic agents in ongoing trials.

Click to read the study JAMA Oncology

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: FLOTgastroesophageal cancerHER2-positive gastroesophageal adenocarcinomaLapatinib
Previous Post

The MR-INFORM trial: fewer patients undergo revascularization when coronary perfusion is assessed with MRI compared to invasive angiography

Next Post

Quick Take: Treatment Outcomes of Immune-Related Cutaneous Adverse Events

RelatedReports

#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males
StudyGraphics

#VisualAbstract: Neoadjuvant chemotherapy plus surgery improves overall survival compared to surgery alone in locally advanced esophageal cancer

December 22, 2021
#VisualAbstract: Positron emission tomography effective at assessing early tumor response to induction chemotherapy in esophageal or esophagogastric junction cancers
StudyGraphics

#VisualAbstract: Positron emission tomography effective at assessing early tumor response to induction chemotherapy in esophageal or esophagogastric junction cancers

December 12, 2021
#VisualAbstract: Fulvestrant-palbociclib and letrozole-palbociclib are equally effective for HR⁺ advanced breast cancer
StudyGraphics

#VisualAbstract: Dose-escalated concurrent chemoradiotherapy does not improve survival in locally advanced esophageal cancer

October 21, 2021
#VisualAbstract: Melanoma survival outcomes have improved between 2003 and 2019 amidst increasing incidence rates
StudyGraphics

#VisualAbstract: Perioperative oxiplatin with S-1 significantly improves survival in patients with advanced gastric cancer or gastroesophageal adenocarcinoma undergoing D2 gastrectomy

September 23, 2021
Next Post
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Quick Take: Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Cognitive outcomes in older adults undergoing cardiovascular procedures unclear

Quick Take: Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery

AAP reaffirms support for adolescents’ rights to confidential reproductive care

Effective adolescent mental health programs incorporate interpersonal skills, emotional regulation, and drug education

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.